Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation
✍ Scribed by Christophe Pasquier; Deborah Anderson; Corinne Andreutti-Zaugg; Rianne Baume-Berkenbosch; Florence Damond; Aviva Devaux; Yvon Englert; Julie Galimand; Carole Gilling-Smith; Odile Guist'hau; Lital Hollander; Marianne Leruez-Ville; Benoit Lesage; Anne Maillard; Anne-geneviève Marcelin; Marie-Paule Schmitt; Augusto Semprini; Maria Vourliotis; Chong Xu; Louis Bujan
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 105 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Couples in whom the man is HIV-1-positive may use medically assisted procreation in order to conceive a child without contaminating the female partner. But, before medically assisted procreation, the semen has to be processed to exclude HIV and tested for HIV nucleic acid before and after processing. The performance was evaluated of the technical protocols used to detect and quantify HIV-1 in 11 centers providing medically assisted procreation for couples with HIV-1 infected men by testing panels of seminal plasma and cells containing HIV-1 RNA and/or DNA. The performance of these tests varied due to the different assays used. False positive results were obtained in 14-19% of cases. The sensitivity for RNA detection in seminal plasma was 500-1,000 RNA copies/ml, over 500 RNA copies/10 6 cells in semen cells, and for DNA detection in semen cells 50-500 DNA copies/10 6 cells. The use of silica-based extraction seemed to increase the assay performance, whereas the use of internal controls to detect PCR inhibitor did not. This first quality control highlights the need for technical improvements of the assays to detect and quantify HIV in semen fractions and for regular evaluation of their performance.